Data on the natural history of such efforts are necessary for physicians to guide shared decision-making with patients and families. We report the survival of consecutive patients with borderline resectable pancreatic cancer who received neoadjuvant therapy before surgery. Read more . . .
It is difficult to successfully deliver multimodality therapy to patients with operable pancreatic cancer.